The karyotypic chaos exhibited by human epithelial cancers complicates efforts to identify mutations critical for malignant transformation. Here we integrate complementary genomic approaches to identify human oncogenes. We show that activation of the ERK and phosphatidylinositol 3-kinase (PI3K) signaling pathways cooperate to transform human cells. Using a library of activated kinases, we identify several kinases that replace PI3K signaling and render cells tumorigenic. Whole genome structural analyses reveal that one of these kinases, IKBKE (IKK3), is amplified and overexpressed in breast cancer cell lines and patient-derived tumors. Suppression of IKK3 expression in breast cancer cell lines that harbor IKBKE amplifications induces cell death. IKK3 activates the nuclear factor-kappaB (NF-kB) pathway in both cell lines and breast cancers. These observations suggest a mechanism for NF-kB activation in breast cancer, implicate the NF-kB pathway as a downstream mediator of PI3K, and provide a framework for integrated genomic approaches in oncogene discovery.
SUMMARY
The karyotypic chaos exhibited by human epithelial cancers complicates efforts to identify mutations critical for malignant transformation. Here we integrate complementary genomic approaches to identify human oncogenes. We show that activation of the ERK and phosphatidylinositol 3-kinase (PI3K) signaling pathways cooperate to transform human cells. Using a library of activated kinases, we identify several kinases that replace PI3K signaling and render cells tumorigenic. Whole genome structural analyses reveal that one of these kinases, IKBKE (IKK3), is amplified and overexpressed in breast cancer cell lines and patient-derived tumors. Suppression of IKK3 expression in breast cancer cell lines that harbor IKBKE amplifications induces cell death. IKK3 activates the nuclear factor-kappaB (NF-kB) pathway in both cell lines and breast cancers. These observations suggest a mechanism for NF-kB activation in breast cancer, implicate the NF-kB pathway as a downstream mediator of PI3K, and provide a framework for integrated genomic approaches in oncogene discovery.
INTRODUCTION
Nearly all epithelial malignancies exhibit numerous karyotypic abnormalities and abundant evidence of widespread genetic alterations. This complexity of genome structure complicates efforts to delineate the roles of these mutations in cancer initiation and maintenance. However, the recent development of several complementary experimental approaches now provides the tools necessary to systematically deconvolute the complexity of somatic cancer genetics.
One experimental approach is to identify genes and proteins that drive cellular transformation through the construction of experimental models of cancer. Together with increasingly sophisticated genetically engineered murine cancer models, human cell-based systems enable the examination of the roles of specific mutations implicated in cell transformation. Recent work indicates that a limited set of genetic changes suffice to transform human cells (Hahn et al., 1999) . Specifically, the coexpression of the telomerase catalytic subunit (hTERT), the SV40 Large T (LT) and small t (ST) oncoproteins, and an activated allele of H-RAS (H-RAS V12 ) render a wide range of human cells tumorigenic (Zhao et al., 2004) . These models have facilitated the identification of candidate oncogenes and tumor suppressor genes (Rowland et al., 2005; Westbrook et al., 2005) . These approaches facilitate the identification of genes that have the potential to drive tumorigenesis but do not alone establish whether these genes truly play a role in human cancer. A second approach is to characterize the genomic alterations seen in cancer specimens using increasingly powerful tools to identify amplifications, deletions, karyotypic rearrangements, and point mutations. Some recurrent amplifications identified by genome scale approaches such as high-density single-nucleotide polymorphism (SNP) arrays and array comparative genomic hybridization (aCGH) contain well-characterized oncogenes such as EGFR and c-MYC (Morrison et al., 2005) . These observations suggest other regions recurrently amplified in human tumors contain other yet-tobe-characterized oncogenes. Indeed, recent applications of these technologies led to the identification of MITF, c-IAP1, and YAP as human oncogenes Zender et al., 2006) . However, amplified regions are often large, spanning several megabases to entire chromosome arms. Therefore, functional tools are needed to pinpoint specific genes that drive transformation targeted by copy-number alterations.
A third approach is the systematic modulation of the expression of genes encoded in regions of chromosomal imbalance. Although such studies have previously required painstaking gene-by-gene analyses, RNA interference (RNAi) now provides the means to define the functional consequences of gene copy-number changes in a rapid and comprehensive manner. Indeed, several large RNAi libraries now exist and have been used to examine the function of genes in a high-throughput manner (Berns et al., 2004; Paddison et al., 2004) , including those necessary for cancer cell viability (Moffat et al., 2006; Ngo et al., 2006) .
In principle, it should be possible to integrate such approaches to develop a framework to identify and validate genes critical to cancer development. Here we have applied such an integrative genomic approach to the Ras signaling pathway. The Ras signaling pathway plays a critical role in coupling inputs from cell-surface receptors to intracellular signaling pathways. Mutations of receptor tyrosine kinases such as EGFR (Lynch et al., 2004; Paez et al., 2004) , of Ras proteins themselves (Downward, 2003) or of proteins in Ras effector pathways including those regulated by Raf/ERK/MAPK (Davies et al., 2002) or PI3K (Samuels et al., 2004) occur in most, if not all, epithelial cancers. Using these integrated approaches, we identify a kinase oncogene, IKBKE, which acts downstream of AKT and is amplified in a substantial percentage of human breast tumors.
RESULTS

Contributions of Ras Effector Pathways to Human Cell Transformation
We previously showed that immortalized human embryonic kidney (HEK) epithelial cells expressing hTERT, LT, and ST (HA1E), are rendered tumorigenic by the introduction of H-RAS V12 (Hahn et al., 1999) . Activation of Ras stimulates many pathways including, but not limited to, the MAPK, PI3K, and RALGDS pathways (Downward, 2003) . However, it is likely that only a subset of these pathways participate directly in H-RAS V12 -induced transformation. Since activating mutations are found in several members of the MAPK and PI3K pathways in many human cancers, we reasoned that the coactivation of these two pathways might replace H-RAS V12 in transformation. To test this hypothesis, we manipulated the MAPK and PI3K pathways in HA1E cells.
To activate the PI3K pathway, we expressed one of three mutant alleles: myristoylated (myr) and therefore constitutively active alleles of PIK3CA p110a (Klippel et al., 1996) (myr-110a) or AKT1 (myr-AKT) (Kohn et al., 1996) or a short hairpin RNA (shRNA) targeting PTEN (Boehm et al., 2005) . To activate the MAPK pathway, we expressed one of three mutant alleles: an activated allele of CRAF (C-Raf 22W) (Stanton et al., 1989) , the BRAF E600 allele (Davies et al., 2002) , or a constitutively active MEK1 D218,D222 allele (MEK DD ) (Brunet et al., 1994) . Using these reagents, we created 16 cell lines expressing all possible combinations of these mutant alleles. We confirmed that these cell lines stably expressed each of these activated alleles either singly or in pairwise combinations (data not shown) and analyzed the ability of these cells to grow in an anchorage-independent (AI) manner or to form tumors in immunodeficient animals (Table 1) . When introduced singly, none of these mutant alleles promoted AI colony formation (Table 1) . However, we found that certain combinations of activated alleles substituted for H-RAS V12 to render these immortalized HEK cells tumorigenic (Table 1) . Specifically, we found that activation of the MAPK pathway by either BRAF E600 or MEK DD expression together with activation of the PI3K pathway by myr-AKT expression induced AI growth indistinguishable from that induced by H-RAS V12 (Table 1, upper panel, and Figure 1) . Surprisingly, while either BRAF E600 or MEK DD cooperated with myr-AKT to induce AI growth, only cells expressing the MEK DD + myr-AKT combination induced tumor growth comparable to that observed in cells expressing H-RAS V12 (Table 1 , lower panel, and Figure 1 ). These observations indicated that coactivation of specific members of the MAPK and PI3K pathways suffices to replace H-RAS V12 in human cell transformation. In these HEK cells, coexpression of MEK DD and myr-AKT most closely recapitulated the tumorigenic phenotype induced by H-RAS V12 (Figure 1 ).
Identification of Transforming Kinases
This approach not only identified specific combinations of activated members of the MAPK and PI3K pathways that replace H-RAS V12 in HEK cell transformation but also established an experimental platform to discover other transforming genes. We extended this work by screening a large collection of genes to identify those that substitute for myr-AKT. Because phosphorylation plays a key role in Ras signalling, we hypothesized that other kinases may participate in PI3K-induced transformation.
To identify such kinases, we created a library of 354 human kinases and kinase-related open reading frames (ORFs), including 256 kinases (Table S1 ), cloned into Gateway-compatible entry vectors (Rual et al., 2004) . Because membrane recruitment via the addition of a myr sequence activates both the PI3K p110a subunit and AKT (Klippel et al., 1996; Kohn et al., 1996) , we created a Gateway-compatible retroviral destination vector, pWN-MF-DEST, which adds a myr sequence and a FLAG-epitope tag (MF) to each introduced ORF. We confirmed that this destination vector and myr tag were functional ( Figure S1 ). We then transferred each ORF individually into pWN-MF-DEST (Figure 2A ).
Using this library of 354 myr ORFs, we performed a screen for genes that could replace myr-AKT and induce transformation. We introduced pools consisting of 10-12 unique ORFs into immortal but nontumorigenic HEK cells expressing MEK DD (HA1E-M). Several pools reproducibly induced colony formation more than two standard deviations greater than the median number of colonies ( Figure 2B ). To determine the identity of the kinases in these pools responsible for AI growth, we then created cell lines expressing individual kinases from each of such pools ( Figure 2C ). Of the four pools analyzed in this manner, three contained one transforming kinase gene and one pool contained two transforming kinase genes. Each of these kinase genes (AKT1, IKBKE, DAK, TSSK6, and CSNK1E) also induced tumor formation ( Figure 2D and data not shown). Since we had previously shown that myr-AKT cooperates with MEK DD to transform these immortalized cells, the identification of AKT1 validated this screening approach. Thus, using a library of myr kinases in retroviral vectors, we identified four kinases that cooperate with activated MEK1 to replace H-RAS V12 in human cell transformation.
Amplification of IKBKE in Breast Cancer Cell Lines and Patient-Derived Tumor Samples
We next explored whether any of these kinases are altered in human cancers. First, we used high-density SNP arrays to identify regions of copy-number gain or loss in 179 cell lines 
Transformation of HEK cells expressing hTERT, the SV40ER plus the indicated constructs. Transformation was assessed by both anchorage-independent growth (upper) and the capacity for tumor formation in immunodeficient mice (lower). representing a wide spectrum of cancer types . We failed to find clear evidence of amplifications of the loci encoding DAK, TSSK6, or CSNK1E in any of these cell lines (data not shown). In contrast, we found copynumber gain or amplification of 1q32 involving the IKBKE locus in 8 of 49 (16.3%) breast cancer cell lines ( Figure 3A) . Indeed, copy-number gain of 1q is the most common alteration in breast cancers (Rennstam et al., 2003) . We next investigated whether IKBKE was similarly amplified in primary human breast cancer specimens by performing aCGH on 30 breast tumors representing different clinicopathological stages (Yao et al., 2006) . These studies also revealed a region of recurrent copy-number gain involving the IKBKE locus on chromosome 1q in 10 of 30 breast tumors ( Figure 3B ). We note that four of the ten ductal carcinoma in situ (DCIS) cases analyzed showed copy-number gain of IKBKE, suggesting that amplification of this locus is an early event in the development of some breast cancers. We failed to find an association of IKBKE copy-number gain with estrogen receptor or Her2/neu status or with the presence of lymph node involvement at diagnosis. In addition, we sequenced the IKBKE gene in 28 breast tumors and 19 breast cancer cell lines and failed to find evidence of somatic mutations, corroborating other sequencing efforts (Bamford et al., 2004) .
To confirm that the region of copy-number gain at 1q32 involves IKBKE, we performed fluorescence in situ hybridization (FISH) on several breast cancer cell lines and a primary breast tumor containing an amplification of 1q32 ( Figure 3C ). We detected up to ten copies of IKBKE in the UACC-812 and ZR-75-1 breast cancer cell lines and five copies of IKBKE in MCF-7 cells. One of the DCIS breast tumors, BWH-T18, harbored five copies of the IKBKE locus in the majority of nuclei ( Figure 3C ).
We also investigated whether these DNA copy-number changes corresponded to increases in IKBKE transcript and protein levels. Indeed, serial analysis of gene expression (SAGE), quantitative RT-PCR, and immunoblotting analyses confirmed that IKBKE (IKK3) is overexpressed in cell lines and breast tumors that exhibited 1q32 gain, suggesting that IKBKE is one target of this amplicon (Figures 3D and 3E and data not shown) . In addition, we found that an additional 13 of 17 cell lines (76.5%) and 10 of 21 breast cancers (47.6%) showed increased expression (>2-fold) of IKBKE transcripts in the absence of 1q32 copy-number changes. Utilizing two different IKK3 antibodies, the observed protein levels correlated with the transcript levels ( Figures 3D and 3E ) and UACC-812 and ZR-75-1 cells, which harbor 1q32 amplifications ( Figures  3A and 3C ), showed the highest levels of IKK3 of any cell line analyzed ( Figure 3E ).
Although our initial experiments were performed in immortalized HEK cells, we also found that the introduction of IKBKE transforms human mammary epithelial cells (HMEC) expressing hTERT, the SV40ER, and MEK DD (HMEC-M) ( Figure 3F ). In addition, since 1q32 amplifications result in increased levels of wild-type (WT) IKBKE, we examined whether forced expression of the WT, nonmyr IKBKE allele also rendered cells tumorigenic. We found that cells expressing WT IKBKE at levels found in human cancer cells exhibited a similar capacity for tumorigenicity ( Figures 2D and 3G) , confirming that the allele amplified in breast cancer specimens is transforming. Together, these observations identified IKBKE as a transforming kinase that is amplified and overexpressed in a substantial fraction of breast cancer cell lines and primary breast tumors.
Consequences of Suppressing IKBKE in Breast Cancer Cells The findings described above implicate IKBKE as breast cancer oncogene. We next sought to explore whether breast cancer cells are functionally dependent on IKBKE expression. The unregulated expression of many oncogenes renders cancer cells unusually dependent upon the continued function of the oncogene for cell proliferation or viability. This property of oncogenes, termed oncogene addiction, provides a rationale for targeting oncogenes therapeutically. To determine whether the presence of IKBKE amplifications and overexpression induces oncogene addiction, we examined the effects of RNAi targeting IKBKE and other genes.
As part of a separate project to systematically discover genes essential for cancer cell viability we have used the shRNA library developed by the RNAi Consortium (TRC) (Moffat et al., 2006) to screen a large collection of genes required for the proliferation of cancer cell lines. As part of this effort, we have screened the MCF-7 breast cancer cell line with 6144 shRNA targeting 1200 genes, including 93% of the human kinome. The results from the screening of MCF-7 cells are of particular relevance to the present study, because this breast cancer cell line harbors a 1q32 copy-number gain ( Figures 3A and 3C ) that results in a modest 2.5-fold increase in IKBKE transcript levels compared to immortalized MCF10A cells ( Figure 3D ). Examining the data from this screen, we found that three of five shRNA targeting IKBKE compromised cell proliferation and viability ( Figures 4A, 4C , and 4D). We found that the level of IKK3 suppression by these five shRNA correlated with the observed decrease in cell proliferation and viability in MCF-7 cells ( Figures 4A, 4C , and 4D). These observations indicate that IKBKE is required for the proliferation and survival of MCF-7 breast cancer cells.
We note that this RNAi screen also included constructs targeting three of the other four genes that emerged from our gain-of-function screen (AKT1, CSNK1E, and TSSK6). Similar to the results from shRNA targeting IKBKE we observed that shRNA targeting AKT1 or CSNK1E also inhibited MCF-7 cell proliferation (data not shown).
We next examined the data generated in the highthroughput RNAi screen to determine whether any other kinase encoded within the 1q32 amplicon was similarly required for MCF-7 viability. We identified a minimally amplified region (5.6 Mb) containing IKBKE in the UACC-812 breast cancer cell line ( Figure 3A ). This minimally amplified region contains nine additional kinase genes. However, RNAi-mediated suppression of these other kinase genes failed to induce a statistically significant decrease in viability of MCF-7 cells ( Figure 4B ). We note that three of four shRNA targeting NUAK2 partially inhibited the proliferation of MCF-7 cells but failed to satisfy the criteria employed to classify significantly decreased proliferation in our high-throughput RNAi screen (See Experimental Procedures). Although these observations do not eliminate the possibility that other genes within this 1q32 amplicon may cooperate with IKBKE to induce transformation, these findings suggest that IKBKE is a key target of the 1q32 amplification in breast cancer cell lines and tumors.
To confirm that these observations in MCF-7 cells applied to other breast cancer cell lines that show IKBKE amplifications, we next examined the ZR-75-1 breast cancer cell line, which exhibits high-level amplification of IKBKE ( Figures 3A and 3C ) and found that inhibition of IKBKE expression in this cell line also compromised viability ( Figure 4C ). In contrast, shRNA-mediated suppression of IKBKE failed to affect viability in PC3 prostate cancer cells, hTERT-expressing HMECs, or the MCF10A.DCIS.com breast cancer cell line, all of which do not harbor amplifications of IKBKE ( Figure 4C ). Corroborating these qualitative observations, we found that suppression of IKBKE in MCF10A.DCIS.com or PC3 cancer cells induced only a small increase in doubling time (9.1%-28.0%) over 11 days (Figure 4D ), while suppression of IKBKE in MCF-7 and ZR-75-1 cells increased doubling time by 80.6%-114.5% ( Figure 4D ). These observations suggested that IKBKE is essential for proliferation in breast cancer cell lines that show increased IKBKE copy number.
IKK3 is a member of a family of five distinct but closely related proteins, the IkB kinase (IKK) family, consisting of IKKa, IKKb, IKKg, IKK3, and TBK1. Since IKK3 function partly overlaps with other IKKs (Fitzgerald et al., 2003; Peters et al., 2000; Sharma et al., 2003) , we next determined whether the proliferation of ZR-75-1, MCF-7, or PC3 cells depended upon expression of any of the other IKK family members. We introduced five shRNA targeting each of these IKK family members into MCF-7, ZR-75-1, and PC3 cells. We required more than one shRNA construct targeting the gene to decrease proliferation (see Experimental Procedures) and found that IKK3 was the only IKK family member required for proliferation of ZR-75-1 cells, while both IKK3 and TBK1 were required for the proliferation of MCF-7 cells ( Figure S2 ). We note that suppression of TBK1 but not IKK3 inhibited the proliferation of PC3 cells.
Together, these observations implicate IKBKE as an essential oncogene in breast cancer cell lines harboring amplifications of 1q32 and are reminiscent of similar findings made in cell lines harboring other oncogenes such as BCR-ABL and EGFR, which also appear to render oncogene-expressing cells particularly dependent upon their expression (Weinstein and Joe, 2006) .
Consequences of IKBKE Amplification and Overexpression
Recent work implicates IKBKE in the innate immune response to viral infections, as it activates the interferon pathway in part by stimulating the activity of the transcription factor IRF3 (Fitzgerald et al., 2003; Sharma et al., 2003) . We tested whether cells expressing IKBKE displayed evidence of increased IRF3 transcriptional activity and found a 3-to 5-fold activation of the IRF3-responsive interferon-stimulated regulatory element (ISRE) of the IFIT2 gene in HA1E-M cells expressing either the myr or WT allele of IKBKE ( Figure S3A ). HA1E-M and HMEC-M cells expressing these IKBKE alleles also showed increased transcription of two known interferon-responsive genes, IFNB1 and CCL5 (encoding RANTES) ( Figures S3B  and S3C) .
To determine whether activation of interferon-responsive promoters was required for transformation induced by IKBKE, we introduced IRF3-specific shRNA constructs into transformed HA1E-M cells expressing myr-IKBKE ( Figure S3D ). The suppression of IRF3 failed to suppress AI growth ( Figure S3E ). These observations suggested that, although the physiologic function of IKBKE involves activation of interferon responses, this activity of IKBKE may not be essential for transformation.
IKBKE also has been reported to activate the NF-kB pathway (Peters et al., 2000) . Thus, we next determined whether the transforming activity of IKBKE is mediated by NF-kB. We examined whether the expression of IKBKE destabilized the cytoplasmic pool of IkBa. HA1E-M cells expressing myr-IKBKE displayed a 43% reduction in cytoplasmic IkBa compared to levels observed in cells expressing a control vector ( Figures 5A and 5B) . Moreover, even when we overexpressed IkBa in these IKBKE-expressing cells, we failed to observe increased IkBa protein expression ( Figure 5C ), indicating that IKK3 effectively drives IkBa degradation. One consequence of IkBa degradation is the translocation of NF-kB transcription factors from the cytoplasm to the nucleus. Consistent with this expectation, we found that HA1E-M cells expressing myr-IKBKE displayed a 32% reduction in cytoplasmic NF-kB p50 ( Figures 5A and 5B) , and 71% of these cells displayed nuclear NF-kB p50 compared to 8% in cells harboring a control vector ( Figures 5D and 5E ).
We also tested whether overexpression of IKBKE induced NF-kB transcriptional activity. HA1E-M cells expressing myr-IKBKE exhibited a 5-fold higher level of NF-kB activity compared to cells expressing a control vector, as assessed by measuring the activity of a synthetic NF-kB reporter gene ( Figure 5F ). To confirm that IKBKE activated the expression of endogenous NF-kB target genes, we measured the expression levels of nine NF-kB target genes in HA1E-M or HMEC-M cells expressing myr-or WT IKBKE, respectively. IKBKE induced increased expression of all of these transcripts compared (C) FISH analysis of IKBKE amplification in UACC-812, ZR-75-1, and MCF-7 breast cancer cell lines and BWH-T18 primary breast tumor. Green signal indicates hybridization using an IKBKE-specific BAC probe, while red color indicates hybridization using a chromosome 1 specific a satellite DNA probe (left panels) or chromosome 1 painting probe (right panels). to cells expressing a control vector ( Figures 6G and 6H ). Since cyclin D1 is overexpressed in over 50% of breast cancers (Bartkova et al., 1994) , we examined whether the observed increases in CCND1 mRNA levels corresponded to increased cyclin D1 protein levels. Indeed, both HA1E-M or HMEC-M cells expressing myr-IKBKE showed substantially elevated levels of cyclin D1 (Figure 5I and data not shown). These data demonstrated that IKBKE activates the NF-kB pathway in two epithelial cell types.
To determine whether activation of the NF-kB pathway is necessary for transformation induced by IKBKE, we inhibited NF-kB activity in IKBKE-transformed HEK cells by expressing a mutant (MUT) ''super-repressor'' allele of IkBa harboring two amino acid substitutions (S32A/ S36A), which renders this MUT IkBa resistant to phosphorylation and degradation (Brown et al., 1995) . Expression of MUT IkBa in IKBKE-transformed HEK cells increased doubling times ( Figure 5J ) and suppressed AI colony formation by 90.7% compared to cells infected with a control vector ( Figure 5K ). In summary, these results implicate the activation of the NF-kB pathway in IKBKEmediated cell transformation.
We initially identified IKBKE as a kinase that replaced AKT in transformation (Figure 2A ). Since AKT has also been reported to activate the NF-kB pathway (Ozes et al., 1999; Romashkova and Makarov, 1999) , we determined if the NF-kB pathway is similarly required for AKTdependent transformation. Introduction of the MUT IkBa allele increased the doubling time of HEK cells transformed by AKT ( Figure 5J ) and suppressed AI growth by 73.9% ( Figure 5K ). We next examined whether IKBKE contributed to cell transformation induced by AKT. Indeed, we found that suppression of IKBKE by two different shRNA constructs increased doubling times by 20.0%-59.0% and inhibited the capacity of AKT-transformed HEK to proliferate and grow in an AI manner ( Figure 5L and data not shown). In aggregate, these observations implicate aberrant activation of the NF-kB pathway by IKBKE as a critical step in cell transformation induced by AKT.
Finally, we determined whether IKBKE regulates the NF-kB pathway in breast cancer cell lines and patientderived breast cancer tissue samples. We first examined changes in NF-kB gene expression after IKBKE suppression in ZR-75-1 and MCF-7 breast cancer cells and found that of the expression of two IKBKE-induced NF-kB regulated genes, MMP9 and BCL2 ( Figures 5G and 5H) , decreased upon suppression of IKBKE ( Figure 6A and data not shown). Breast cancer cell lines harboring the 1q32 amplification showed increased expression of these genes compared to a breast cancer cell line that lacks IKK3 expression (SUM52; Figures 3E, right panel, 6B , and 6C). We next confirmed that these observations in cell lines also extended to primary breast cancer specimens. Since IKK3 has recently been shown to induce nuclear accumulation of the NF-kB family member c-REL (Harris et al., 2006) , we performed immunohistochemistry (IHC) to detect IKK3 and c-REL in an independent set of 20 breast cancer tissue samples. We found that 7 of 20 (35%) of these breast cancer specimens showed increased expression of IKK3 ( Figures 6D and 6E) , confirming our observations in the initial breast cancer specimens ( Figures 3B and 3D ). In addition, we found that seven of seven (100%) breast tumors that exhibited increased IKK3 expression also displayed nuclear c-REL. In contrast, c-REL was expressed at very low levels or was predominantly located in the cytoplasm in 12 of 13 (92%) of breast tumors that do not exhibit increased IKK3 expression ( Figures 6D and 6E ). This correlation between IKK3 expression and nuclear localization of c-REL was statistically significant (p < 0.0084). Together, these observations demonstrated that IKK3 activates the NF-kB pathway in breast cancer.
DISCUSSION
Identification of IKBKE as a Human Breast Cancer Oncogene
Mutations of proto-oncogenes and tumor suppressor genes allow incipient cancer cells to escape the normal mechanisms that regulate cell and tissue homeostasis. In particular, kinase oncogenes play essential roles in many, if not all, human cancers and therefore are particularly attractive therapeutic targets. Indeed, several kinase inhibitors are already in clinical use. Based on these examples, several properties identify oncogenes with particular promise for clinical translation including clear evidence that mutation, amplification, or translocation of the putative oncogene occurs in primary tumors and functional confirmation that cancer cells exhibit an unusual dependence upon the oncogene for viability or proliferation.
Here, we identify IKBKE as a human breast cancer oncogene. IKBKE is amplified and overexpressed in a significant percentage of human breast tumors. In addition, IKBKE expression leads to cell transformation when overexpressed in immortalized human cells at levels found in breast cancer specimens, and cancer cell lines that exhibit IKBKE copy-number gain or amplification require IKK3 expression for viability. Together, these observations strongly support the conclusion that amplifications of IKBKE play an important role in the pathogenesis of a subset of breast tumors and identify IKK3 as promising cancer target.
IKBKE, NF-kB and Breast Cancer
Prior studies have shown that activation of the NF-kB pathway occurs in a significant percentage of human cancers (Karin et al., 2002) and specifically in breast tumors (Biswas et al., 2004; Sovak et al., 1997) . Although members of the NF-kB signaling pathway including IKBKB, CARD11, MALT1, and BCL10 are required for the survival and proliferation of specific diffuse large B cell lymphoma cell lines (Ngo et al., 2006) , the mechanism responsible for increased NF-kB activity in human breast tumors remained undefined (Karin et al., 2002) . By examining breast cancer cell lines and breast cancer tissue specimens, we found that overexpression of IKK3 activates the NF-kB signaling pathway and that this activity is necessary for the transforming potential of IKK3. Furthermore, the observation that IKK3 expression strongly correlates with nuclear localization of c-REL in primary breast cancer specimens suggests that a significant fraction of NF-kB activation in breast cancer is driven by aberrant expression of IKK3. These observations corroborate prior reports that showed that IKK3 directly activates c-REL (Harris et al., 2006) or other NF-kB family members (Adli and Baldwin, 2006; Eddy et al., 2005) and that c-REL accumulates in nuclei of breast cancer cells (Sovak et al., 1997) .
Although IKK3 is a member of the IKK family, IKK3 phosphorylates only one of two serine residues in IkBa necessary for ubiquitination and degradation of IkBa (Peters et al., 2000) . Since IKK3 participates in the activation of innate immune responses mediated by IRF3 and IRF7 (Fitzgerald et al., 2003; Sharma et al., 2003; Tenoever et al., 2007) , a key physiological function of IKK3 and the closely related family member TBK1 is likely to be related to innate immunity. More recently, the Drosophila IKK family member most closely related to IKK3, called DMIKK3, appears to play several roles in development including activation of nonapoptotic caspase function by phosphorylation of DIAP1 , F actin assembly (Oshima et al., 2006) , and mRNA localization during oogenesis (Shapiro and Anderson, 2006) . Although the MUT IkBa (super-repressor) construct blocked IKK3-dependent AI growth, further work is necessary to determine whether other pathways regulated by IKK3 also contribute to the tumorigenic phenotype in breast and other cancers.
While several breast cancer cells required IKK3 for survival, some cancer cells including PC3 cells appear to depend upon the expression of TBK1 for proliferation. Although we failed to observe amplifications involving the TBK1 locus (data not shown), it remains possible that these IKKs interact or functionally substitute for each other since these two noncanonical IKK family members share similar functions in other assays (Fitzgerald et al., 2003; Sharma et al., 2003) . A recent report identifies TBK1 as a component of the RalB/Sec5 exocyst complex and indicates that TBK1 is essential for H-RAS V12 -induced transformation (Chien et al., 2006) . Since several members of the canonical NF-kB signaling pathway are altered in human leukemia and lymphomas (Karin et al., 2002) , these findings indicate that NF-kB activation may occur by distinct mechanisms in different tumor types. We found that breast cancer cell lines harboring 1q32 amplification and expressing high levels of IKK3 exhibit exquisite sensitivity to suppression of IKK3 expression. In contrast, we observed that suppression of IKK3 in other cancer cell lines lacking significant 1q32 amplifications failed to affect viability and proliferation. We note, however, that a dominantly interfering IKBKE allele suppresses AI proliferation of a breast cancer cell line without 1q32 amplification (Hs 578T) (Eddy et al., 2005) , and IKBKE suppression in HeLa cells leads to apoptosis (Adli and Baldwin, 2006; MacKeigan et al., 2005) . Both Hs 587T and HeLa cells express elevated levels of IKK3 (Adli and Baldwin, 2006; Eddy et al., 2005) . Since we found that several breast tumors overexpress IKBKE yet lacked amplifications ( Figure 3D ), these observations suggest that other alterations beyond copy-number alterations also lead to increased IKBKE expression and/or activity in some cancer cell lines and tumors.
IKBKE Replaces AKT in Transformation
We found that IKBKE replaces AKT in transformation and that AKT-driven cell transformation requires NF-kB activity and IKBKE. These observations implicate IKBKE and the NF-kB pathway as a key effector pathway triggered by AKT signaling in transformation. Although previous reports demonstrated that AKT activation of NF-kB involves direct activation of the canonical IKK complex (Ozes et al., 1999; Romashkova and Makarov, 1999) , our observations suggest that in some cell types AKT and IKK3 are functionally related.
In addition to IKBKE, we identified three other kinases (DAK, TSSK6, and CSNK1E) that replaced activated AKT1 in an experimental model of human cell transformation. Further work may determine that DAK, TSSK6, or CSNK1E are altered in human tumors. Furthermore, identifying genetic alterations that cooperate with IKBKE amplification in breast cancer may pinpoint other pathways that synergize with this oncogene.
Dissection of Ras Signaling
To identify kinases that replace myr-AKT in human cell transformation, we determined whether activation of the PI3K and MAPK pathways would cooperate to replace H-RAS V12 in an experimental model of human cell transformation. Previous studies using similar transformation systems used three mutant H-RAS V12 alleles that preferentially activate the PI3K, MAPK, or RALGDS pathways and identified an important role for the pathway regulated by RALGDS in H-RAS V12 -induced AI growth in several types of human cells (Hamad et al., 2002; Rangarajan et al., 2004) . However, the further activation of the MAPK or PI3K pathway in these experiments was necessary to permit such engineered cells to form tumors. Although activated MEK and AKT alleles cooperated to replace H-RAS V12 in human cell transformation, we also found that the expression of some activated alleles within the PI3K and MAPK pathways failed to cooperate to induce tumorigenic potential. For example, although either BRAF E600 or MEK DD cooperated with myr-AKT to confer AI growth, BRAF E600 failed to cooperate with myr-AKT to promote tumor formation (Table 1) . Since BRAF mutations
have not yet been identified in renal cancer but are frequently observed in other malignancies such as melanoma, these observations are consistent with the view that particular combinations of Ras effector pathway mutations cooperate in specific cell types (Rangarajan et al., 2004) . Alternatively, since accumulating evidence suggests that activation of specific Ras effector pathways leads to feedback inhibition (Courtois-Cox et al., 2006) , these observations may reflect lineage-specific feedback loops.
Functional Genomics and Integrating Complementary Genomic Approaches
The development of methodologies to identify genetic alterations at genome scale promises to provide a comprehensive view of cancer-associated mutations. However, a full appreciation of these genetic alterations will require equally efficient high-throughput methods to assess the functional consequences of these genetic changes and to evaluate them as potential therapeutic targets. The development of genome-scale libraries of RNAi reagents has facilitated loss-of-function approaches in mammalian cells that have identified candidate tumor-suppressor genes (Kolfschoten et al., 2005; Westbrook et al., 2005) . In parallel to these loss-of-function approaches, candidate oncogenes have been identified using screening tools such as cDNA libraries derived from cancer cells or the use of viral integration to activate endogenous genes (Dupuy et al., 2006; Peeper et al., 2002 ).
Here we have combined both gain-of-function and lossof-function approaches with whole-genome characterization of genetic alterations in cancer cell lines and tumors. This integrated approach permitted us both to identify IKBKE as a breast cancer oncogene amplified in a significant percentage of human breast tumors and to verify its functional role in mammary cell transformation. Similarly, other recent reports highlight the power of integrating complementary genomic approaches to identify genes associated with oncogenesis Zender et al., 2006) and metastasis . Together, these reports suggest a framework for comprehensive approaches to annotate structural and functionally important genetic alterations essential for cancer development while efficiently validating targets of particular promise for clinical translation.
EXPERIMENTAL PROCEDURES
Cell Culture, Vectors, and Retroviral Infection HEK cells (Hahn et al., 1999) and HMECs expressing hTERT (Elenbaas et al., 2001 ) have been described. To introduce or suppress specific genes, retroviral (pBabe, pWzl, and pMKO) (Boehm et al., 2005; Morgenstern and Land, 1990) or lentiviral (pLKO) (Moffat et al., 2006) vectors were used. Retroviruses and lentiviruses were generated as described (Boehm et al., 2005; Moffat et al., 2006) . Details regarding cell-culture conditions and retroviral vector construction are described in the Supplemental Experimental Procedures. Tumor specimens and breast cancer cell lines were obtained as described (Yao et al., 2006) .
Myristoylated Kinase Library
ORFs were cloned into Gateway-compatible pEntry vectors by performing site-specific BP recombination reactions as described (Rual et al., 2004) . pWzl-Neo-Myr-Flag DEST (pWN-MF-DEST) was created by inserting an N-terminal myr-FLAG tag and the Gateway-selectable cassette into the pWzl-Neo retroviral vector. To create specific pWN-MF-ORF vectors, site-specific LR recombination reactions were performed individually as described (Rual et al., 2004) .
AI Growth and Tumorigenicity Assays
Growth of cells in soft agar was determined by plating 5 3 10 4 cells in triplicate in 0.4% (HEK) or 0.3% (HMEC) Noble agar. Colonies greater than 100 mm in diameter were counted microscopically 8 weeks after plating. Colonies greater than 200 nm in diameter were counted macroscopically 8 weeks after plating. Tumor xenograft experiments were performed as described (Boehm et al., 2005) . Tumor injection sites were monitored for 80 days for tumor formation.
Immunoblotting and PCR Immunoblotting was performed as described (Boehm et al., 2005) . The following antibodies were used: anti-IKK3 K-14 (Santa Cruz, CA) (Figure 3) or anti-IKK3 c-terminal (Sigma) (Figures 3-6 ), anti-IkBa C-15 (Santa Cruz, CA), anti-NF-kB H-119 (Santa Cruz, CA), anti-MEK1/2 (Cell Signaling), anti-Cyclin D1 (Neomarkers), or anti-IRF3 (Santa Cruz, CA). For RT-PCR, total RNA was isolated using TRIzol (Invitrogen). For quantitative RT-PCR, we used SYBR-Green (Applied Biosystems). A list of primers may be found in Supplemental Experimental Procedures.
IHC
Breast cancer tissue microarray slides (Biomax BR803) were immunostained with anti-IKK3-C-terminal (1:250; Sigma) and anti-c-Rel C terminus (1:200; Chemicon) antibodies using microwave-citrate antigen retrieval followed by standard IHC staining procedures. Arrays were scored in a blinded manner by a pathologist on a scale of 0-3.
Genome Structure Analyses SNP array, aCGH, and SAGE data were collected and analyzed as described .
RNAi
To stably suppress IKBKE and other members of the IKK family we used pLKO.1 lentiviral shRNA constructs generated by TRC (Moffat et al., 2006) . Lentiviral infections were performed as described (Moffat et al., 2006) . Cell Titer Glo (Promega) was used to measure viability 5 days after lentiviral infection. Z scores were calculated by normalizing the viability score of each well to the plate mean viability score and standard deviation (SD) of plate viability scores: Z = (X-m)/s, where X = assay value (relative luminescence), m = mean plate viability score, and s = SD of plate viability scores. Suppression of viability was defined as the capacity for at least one shRNA to decrease viability more than 1.5 SD below the mean Z score and at least one additional shRNA targeting the same kinase to decrease viability more that 1 SD below the mean Z score.
Supplemental Data
Supplemental Data include three figures, one table, and Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at http://www.cell.com/cgi/content/full/ 129/6/1065/DC1/.
